Item 4.01 Changes in Registrant’s Certifying Accountant.
(a) Dismissal of Independent Registered Public Accounting Firm
On January 17, 2023, Kho &
Patel, Certified Public Accountants, (“Kho”), resigned as the independent registered public accounting firm of Vitaspring
Biomedical Co. Ltd. (the “Company”).
Kho & Patel's report on
the financial statements for the fiscal years ended January 31, 2022 and January 31, 2021, the last reports issued by Kho, contained no
adverse opinion or disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principle, other
than an explanatory paragraph as to a going concern.
During the fiscal the years
ended January 31, 2022 and January 31, 2021, and in the subsequent interim periods October 31, 2022, July 21, 2022 and April 30, 2022,
through January 17, 2023, the date of the resignation of Kho & Patel, (a) there were no disagreements with Kho & Patel on any
matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not
resolved to the satisfaction of Kho & Patel, would have caused them to make reference to the subject matter of the disagreements in
its reports on the financial statements for such year and (b) there were no reportable events as defined in Item 304(a)(1)(v) of Regulation
S-K.
We have provided a copy of the
disclosures contained herein to Kho & Patel on January 27, 2023, and requested Kho & Patel to provide it with a letter addressed
to the U.S. Securities and Exchange Commission stating whether or not Kho & Patel agrees with the above disclosures. A copy of Kho
& Patel’s response letter is attached hereto as Exhibit 16.1.
(b) New Independent Registered Public Accounting
Firm
On January 24, 2023, our board
of directors approved the engagement of TAAD LLP (“TAAD”), as the Company’s new independent registered public accounting
firm.
During the Company’s most
recent fiscal year end and any subsequent interim period preceding the engagement of TAAD, neither the Company nor anyone acting on our
behalf, has consulted with TAAD regarding either: (i) the application of accounting principles to a specified transaction, either contemplated
or proposed, (ii) the type of audit opinion that might be rendered on the Company’s financial statements, or (iii) any matter that
was either the subject of a disagreement between the Company and TAAD as described in Item 304(a)(1)(iv) of Regulation S-K or a reportable
event as described in Item 304(a)(1)(v) of Regulation S-K.
